Used in the treatment of various autoinflammatory diseases, particularly cryopyrin-associated periodic syndromes (CAPS), including Muckle-Wells syndrome, familial cold autoinflammatory syndrome, and neonatal-onset multisystem inflammatory disease. It is also indicated for the treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS), and familial Mediterranean fever (FMF) in patients who are not responding adequately to conventional therapy. Additionally, it has been studied for its role in reducing cardiovascular events in patients with a history of myocardial infarction and elevated C-reactive protein levels, showing potential in atherosclerosis management. Its mechanism involves neutralizing interleukin-1 beta, a key mediator in systemic inflammation, thereby controlling excessive inflammatory responses.